ARCHIVES

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

NCI-Approved Clinical Trials

August 31, 2001

Cooperative Groups Not Included Among Grants to Be Funded At Recommended Levels

November 11, 1983

Biotheraputics Inc. Markets ‘Custom Made’ Experimental Therapy

August 9, 1985

AACR 2001 Honorary Awards Announced; Nora Janjan Is ASTRO President-Elect.

January 5, 2001

Von Eschenbach Says He Will Step Down as NCI Director; No Acting Director Has Been Named.

March 24, 2006

House Subcommittee To Hold Hearings On Cancer Program

June 10, 1977